PN-235 is under clinical development by Protagonist Therapeutics and currently in Phase II for Plaque Psoriasis (Psoriasis Vulgaris). According to GlobalData, Phase II drugs for Plaque Psoriasis (Psoriasis Vulgaris) have a 47% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PN-235’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PN-235 is under development for the treatment of inflammatory bowel disease and plaque psoriasis. It is administered by the oral route. The drug candidate acts by targeting IL-23 receptor and being developed based on the peptide technology platform.
Protagonist Therapeutics overview
Protagonist Therapeutics (Protagonist) is a clinical-stage biopharmaceutical company that discovers and develops orally stable peptides as targeted therapies. The company through its proprietary technology platform develops structurally novel oral or injectable peptides for protein-protein interaction targets. Protagonist’s peptides specifically target biological pathways that are also targeted by currently marketed injectable antibody drugs. Protagonist’ product candidates are intended for the treatment of inflammatory bowel disease and other gastrointestinal diseases and hematological disorders. The company has its operations in the US and Australia. Protagonist is headquartered in Milpitas, California, the US.
For a complete picture of PN-235’s drug-specific PTSR and LoA scores, buy the report here.